Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case ‐cohort

ConclusionsCYP4F2 polymorphism was associated with major bleeding, especially in combination withVKORC1 genetic variants. These variants could be considered to further personalize anticoagulant treatment.

Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 1, 2024 Category: Drugs & Pharmacology Authors: Eleonora Camilleri, Mira Ghobreyal, Mettine H. A. Bos, Pieter H. Reitsma, Felix J. M. Van  Der Meer, Jesse J. Swen, Suzanne C. Cannegieter, Nienke van Rein Tags: RESEARCH ARTICLE Source Type: research